Study of Levofloxacin and Cefoperazone-Sulbactam Utilization Cost on Patients with Mild and Moderate Corona Virus Disease-2019

Abstract

Covid-19 is a highly infectious disease caused by SARS Cov-2. Antibiotics are sometimes given as therapy to patients when there is a secondary bacterial infection. The purpose of this study was to determine the treatment costs associated with using antibiotics Levofloxacin and Cefoperazone Sulbactam for mild to moderate COVID-19 patients at Bhayangkara H.S Samsoeri Mertojoso Hospital in Surabaya. For mild COVID-19 patients who receive levofloxacin antibiotic therapy, the total cost of treatment is IDR. 66,648,632 with a length of stay of 9 days. For patients with moderate degrees of COVID-19, the total cost of treatment is Rp. 81,339,295 with 10 days of hospitalization. For mild COVID-19 patients who receive cefoperazone sulbactam antibiotic therapy, the total cost of treatment is IDR. 81,401,005 with a length of stay of 11 days. For patients with moderate degrees of COVID-19, the total medical costs are Rp. 71,613,107 with 9 days of hospitalization. Based on the evaluation of research results, mild COVID-19 patients can receive levofloxacin antibiotic therapy, while moderate COVID-19 patients can receive cefoperazone sulbactam antibiotic therapy because it is cheaper and results in a shorter length of stay.